News and updates

December 5, 2018

PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium IRVINE, CA, AMSTERDAM, NETHERLANDS – 28 November 2018 – Agendia, Inc., a world leader in precision oncology, will present new data reinforcing the…

December 4, 2018

PRESS RELEASE Oncology Consultants Join Agendia’s FLEX Big DataRegistry Study, Helping to Build a Unique Resource for Breast Cancer Research All Oncology Consultants practices participate in the initiative, matching full genome profiles with complete clinical data to create a comprehensive patient database IRVINE, CALIF., U.S., HOUSTON, TEXAS, U.S., AMSTERDAM, NETHERLANDS – 4 December 2018 –…

November 14, 2018

 PRESS RELEASE Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients New data from the trial shows that a subgroup of “ultra-high risk” patients identified by MammaPrint respond better to certain targeted therapies and treatment combinationsIn a separate I-SPY…

October 9, 2018

PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines The NCCN recommends Agendia’s MammaPrint® breast cancer test with the highest level of evidence for early-stage breast cancer patients with estrogen receptor-positive, lymph-node negative and lymph-node positive (LN+ 1-3)  MammaPrint is now the only genomic…